Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses.
10.1016/j.apsb.2020.08.004
- Author:
Yunkai YANG
1
;
Xiaohan GUO
1
;
Bo HU
2
;
Peng HE
1
;
Xiaowu JIANG
3
;
Zuohuan WANG
4
;
Huaxing ZHU
2
;
Lina HU
5
;
Minghua YU
5
;
Meiqing FENG
1
Author Information
1. Shanghai Engineering Research Center of ImmunoTherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
2. Shanghai Novoprotein Biotechnology Co., Ltd., Shanghai 201203, China.
3. Medical School of Yichun University, Yichun 336000, China.
4. Clinical Research Center, 2nd Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310009, China.
5. Department of Oncology, Shanghai Pudong Hospital, Fudan University Pudong Medicine Center, Shanghai 201399, China.
- Publication Type:Journal Article
- Keywords:
Cancer vaccine;
Dendritic cells;
NY-ESO-1;
SecPen;
Ubiquitin
- From:
Acta Pharmaceutica Sinica B
2021;11(2):476-487
- CountryChina
- Language:English
-
Abstract:
Dendritic cell-based cancer vaccines (DC vaccines) have been proved efficient and safe in immunotherapy of various cancers, including melanoma, ovarian and prostate cancer. However, the clinical responses were not always satisfied. Here we proposed a novel strategy to prepare DC vaccines. In the present study, a fusion protein SNU containing a secretin-penetratin (SecPen) peptide, NY-ESO-1 and ubiquitin was designed and expressed. To establish the DC vaccine (DC-SNU), the mouse bone marrow-derived DCs (BMDCs) were isolated, pulsed with SNU and maturated with cytokine cocktail. Then peripheral blood mononuclear cells (PBMCs) from C57BL/6 mice inoculated intraperitoneally with DC-SNU were separated and cocultured with MC38/MC38
